Company intelligence / Profile preview

Viracta Therapeutics, Inc.

Cardiff, California, United Statesviracta.com ↗

Ownership: Public · VIRX
Development stage: Phase 2

Overview

In their Phase 2 NAVAL-1 trial for EBV+ PTCL, they reported overall and complete response rates of 33% and 19% respectively, with higher rates (60% ORR, 30% CRR) in second-line patients[9]. The company terminated operations in February 2025[7].

Therapeutic areas: Oncology
Modalities: Small molecules (HDAC inhibitor)Antiviral agents
Industry: Biotech

Drug pipeline

2 assets

nanatinostat

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $388.7K
Total revenue: $0
Enterprise value: $-3.8M

Beyond the preview

Go deeper on Viracta Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Viracta Therapeutics, Inc..

Explore the full profile